Generics Safe Harbor Question Could Derail Biosimilars
Biologic drug sponsors may have a powerful weapon to block competition from cheaper biosimilars, experts say, if they can successfully argue that the generic drug law's safe harbor from patent infringement...To view the full article, register now.
Already a subscriber? Click here to view full article